Annual results show diverging trends in scale and profitability. Revenue rose from KRW 179.7 billion in 2022 to KRW 196.3 billion in 2023 (up 9.3% year on year) and KRW 219.7 billion in 2024 (up 11.9%), then fell to KRW 210.3 billion in 2025 (down 4.3%).
Operating profit was KRW 4.02 billion in 2022 and KRW 6.47 billion in 2023 (up 61.1%), but dropped to KRW 113 million in 2024 (down 98.3%). For 2024, the company attributed the drop to higher personnel and operating costs at the Vietnam subsidiary as it prepared for commercial production.
In 2025 the company swung to an operating loss of KRW 22.2 billion, with an operating margin of -10.6%.
Net income attributable to controlling shareholders was a loss of KRW 28.29 million in 2022, a profit of KRW 1.66 billion in 2023 (a swing into profit), a loss of KRW 5.63 billion in 2024 (a swing into loss) and a loss of KRW 34.7 billion in 2025 (losses continued and widened).
Losses have occurred in 2024 and 2025 for two consecutive years, and net income including non-controlling interests followed the same pattern.
SK Securities cited the 2025 loss widening to the suspension of Afilibu sales amid a patent dispute, about KRW 3 billion in one-time clinical costs, and lost sales tied to delayed GMP certification of the Vietnam CMO plant.
Operating cash flow was KRW 4.15 billion in 2022, KRW 11.7 billion in 2023, KRW 2.59 billion in 2024 and KRW 568 million in 2025.
Quarterly, the operating loss widened to KRW 5.15 billion in the third quarter of 2025 and KRW 8.57 billion in the fourth quarter, then narrowed to KRW 8.38 billion, KRW 6.33 billion and KRW 3.19 billion in the first through third quarters of 2026, each narrowing versus the prior quarter.
Third-quarter 2026 revenue was KRW 51.4 billion, up 0.5% year on year, and the net loss attributable to controlling shareholders was KRW 6.4 billion, down from KRW 7.93 billion a year earlier.
The net loss attributable to controlling shareholders over the last four quarters (fourth quarter 2025 to third quarter 2026) totaled KRW 36.1 billion. For January through September 2026, revenue was KRW 154.57 billion (down 1.7% year on year) and operating loss was KRW 17.9 billion (widened year on year).
The company attributed the cumulative operating loss mainly to selling and administrative costs at the Vietnam subsidiary, including KRW 4.8 billion in depreciation and KRW 1.7 billion in repairs. These figures come from the quarterly report filed on November 16, 2026.